Elizabeth Jackson
Adult Health · Temple, TXNPI 1659696003
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 55.4% of the total. Reporting peaked in 2022 at $13,170 and has fallen 95.3% since, to $620 in 2025. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $67.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$12K
- Regeneron Healthcare Solutions, Inc.$3K
- Novartis$2K
- Amgen$923
- Boehringer Ingelheim$576
- Novo Nordisk$530
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,17010%
- Speaking & faculty fees$8,83040%
- Travel & lodging$2,79012%
- Food & beverage$8,53738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 51 | $12,364 |
| Regeneron Healthcare Solutions, Inc. | 21 | $3,203 |
| Novartis | 80 | $2,370 |
| Amgen | 32 | $923 |
| Boehringer Ingelheim | 23 | $576 |
| Novo Nordisk | 13 | $530 |
| Pfizer | 22 | $390 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $348 |
| AstraZeneca | 17 | $338 |
| Regeneron | 4 | $219 |
| Johnson & Johnson | 14 | $213 |
| Alnylam Pharmaceuticals Inc. | 4 | $192 |
| Impulse Dynamics (USA) Inc. | 11 | $186 |
| Bayer | 4 | $91 |
| Amarin Pharma, Inc. | 4 | $88 |
| Astellas Pharma US Inc | 2 | $48 |
| Abbott | 1 | $47 |
| Abiomed | 1 | $39 |
| Merck | 1 | $30 |
| Cvrx, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Medicure Pharma Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Althera Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,327 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $209,450 |
| MounjaroTirzepatide | 111 | $135,066 |
| Repatha SureclickEvolocumab | 113 | $128,368 |
| JardianceEmpagliflozin | 60 | $92,172 |
| FarxigaDapagliflozin Propanediol | 35 | $40,729 |
| Praluent PenAlirocumab | 23 | $27,741 |
| Repatha SyringeEvolocumab | 17 | $22,354 |
| EliquisApixaban | 17 | $21,606 |
| WegovySemaglutide | 14 | $18,904 |
| VascepaIcosapent Ethyl | 16 | $12,959 |
| Icosapent Ethyl | 22 | $9,231 |
| Ezetimibe | 275 | $8,052 |
| Rosuvastatin Calcium | 254 | $5,267 |
| Pioglitazone Hcl | 91 | $3,277 |
| Atorvastatin Calcium | 124 | $2,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $530 | $228,354170 claims |
| Boehringer IngelheimJardiance | $576 | $92,17260 claims |
| AstraZenecaFarxiga | $338 | $40,72935 claims |
| PfizerEliquis | $390 | $21,60617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Temple
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.